Zdrowie i gospodarka · 14/01/2002

FDA Reclassifies Automated Differential Cell Counter from Class III to Class II

The FDA is reclassifying the automated differential cell counter from a Class III device requiring premarket approval to a Class II device with special controls, following a reclassification petition from the International Society for Laboratory Hematology, to ensure the safety and effectiveness of the device.